BillionaireNet
Tabuteau
Herriot Tabuteau
Rank #2692
UNITED STATESHealthcareHealthcare

Herriot Tabuteau

Net Worth
$1.3B
-0.69% (24h)
Herriot Tabuteau is a Haitian-born American, and the founder and CEO of Axsome Therapeutics. As of 2024, he has an estimated net worth of $1.3 billion. Tabuteau's career includes healthcare finance, with experience at Goldman Sachs and as a partner at a hedge fund. He is the inventor on over 200 patents, including potential new medicines for depression and Alzheimer's disease. Tabuteau's primary achievement is founding Axsome Therapeutics in 2012, focusing on treatments for brain disorders, and bringing innovative therapies to market, making him a pioneer in modern medicine.

The Full Dossier

Early Life

Herriot Tabuteau was born in Haiti and immigrated to the United States at the age of nine. He grew up in Manhattan's Upper East Side, surrounded by medical institutions like Rockefeller University and Memorial Sloan Kettering Cancer Center. This environment fostered his early interest in science. He attended Xavier High School and graduated from Wesleyan University with a degree in molecular biology and biochemistry.

Rise to Success

Tabuteau's career began in healthcare finance, where he gained experience at Goldman Sachs and later as a partner at the healthcare hedge fund Healthco/S.A.C. Capital. In 2012, he founded Axsome Therapeutics, with a focus on developing treatments for central nervous system disorders. Axsome went public in 2015. His work led to the development and commercialization of Auvelity, a groundbreaking antidepressant, and other drugs for Alzheimer's disease.

Key Business Strategies

Tabuteau's strategy involved focusing on brain disorders, often neglected by the pharmaceutical industry. He built a portfolio approach, and ran clinical trials in-house to reduce costs. He also made smart acquisitions, such as Sunosi in 2022.

Philanthropy

Specific philanthropy amounts could not be found, but Tabuteau's work focuses on improving the lives of those affected by neurological and psychiatric disorders.

Career Timeline

2025

Symbravo FDA Approved

Symbravo (meloxicam and rizatriptan) received FDA approval for the acute treatment of migraines with or without auras.

2022

Auvelity FDA Approved

Auvelity, a novel antidepressant, received FDA approval.

2015

Axsome Therapeutics Goes Public

Took Axsome Therapeutics public on the NASDAQ.

2012

Founded Axsome Therapeutics

Founded Axsome Therapeutics with the goal of developing treatments for brain disorders.

Philanthropic Impact

HealthcareUndisclosed

Focus on Brain Disorders

Dedicated to improving the lives of those affected by neurological and psychiatric disorders.

Wealth Trajectory